PI
SAGE

Putnam Investments’s Sage Therapeutics SAGE Stock Holding History

Putnam Investments’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,488
Closed -$338K – 1201
2022
Q2 		$338K Buy
+10,488
New +$352K ﹤0.01% 1061
2020
Q3 		– Sell
-47,983
Closed -$2M – 890
2020
Q2 		$2M Buy
+47,983
New +$1.74M ﹤0.01% 678
2018
Q2 		– Sell
-9,562
Closed -$1.54M – 1174
2018
Q1 		$1.54M Buy
9,562
+3,579
+60% +$608K ﹤0.01% 770
2017
Q4 		$986K Buy
+5,983
New +$580K ﹤0.01% 890
2017
Q2 		– Sell
-6,995
Closed -$497K – 1268
2017
Q1 		$497K Sell
6,995
-1,629
-19% -$95.4K ﹤0.01% 1109
2016
Q4 		$440K Buy
8,624
+261
+3% +$12.3K ﹤0.01% 1139
2016
Q3 		$386K Sell
8,363
-11,067
-57% -$450K ﹤0.01% 1158
2016
Q2 		$586K Sell
19,430
-124
-0.6% -$4.13K ﹤0.01% 1176
2016
Q1 		$627K Buy
19,554
+106
+0.5% +$3.73K ﹤0.01% 1200
2015
Q4 		$1.13M Sell
19,448
-358
-2% -$17.7K ﹤0.01% 1130
2015
Q3 		$838K Buy
19,806
+500
+3% +$30.8K ﹤0.01% 1214
2015
Q2 		$1.41M Buy
+19,306
New +$1.24M ﹤0.01% 1148

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Putnam Investments's SAGE Position: Q3 2022 in Review

Putnam Investments sold out of Sage Therapeutics (SAGE) in Q3 2022, closing a stake of 10,488 shares — an estimated $338K sold.

Putnam Investments first reported a position in SAGE in Q2 2015 and held it in 12 quarters. The position peaked at $2M in Q2 2020. 201 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

  • Putnam Investments reported no remaining Sage Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Putnam Investments sold 10,488 Sage Therapeutics shares in Q3 2022, an estimated $338K.
  • Putnam Investments first reported a position in Sage Therapeutics in Q2 2015 and held it in 12 quarters.
  • Putnam Investments's Sage Therapeutics position peaked at $2M in Q2 2020.
  • 201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on Putnam Investments's 13F filing for Q3 2022, filed 14 Nov 2022.